NDAORALTABLET
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
COMBOGESIC (acetaminophen and ibuprofen) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for minor aches, pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC is an oral tablet combining acetaminophen and ibuprofen, two cyclooxygenase inhibitors approved in March 2023. It treats minor aches and pains including headache, toothache, backache, menstrual cramps, muscular aches, and minor arthritis pain through dual NSAID and analgesic mechanisms. The fixed-dose combination leverages complementary pharmacology to enhance pain relief efficacy.
Peak12.7 years to LOE
COMBOGESIC is in peak revenue phase with ~12.7 years of patent protection remaining, suggesting sustained commercial investment and team stability through 2036.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on COMBOGESIC at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.